US Government Increase Orders for Flu Treatment from Roche, GSK
The US Department of Health and Human Services (HHS) (Washington, DC, www.hhs.gov) ordered additional purchases of antiviral drugs that could be used in the event of an influenza pandemic. The department ordered 2.2 million more treatment courses of “Relenza” (zanamivir) from GlaxoSmithKline PLC (London, England, www.gsk.com) and 3.8 million more treatment courses of “Tamiflu” (oseltamivir) from Roche (Basel, Switzerland, www.roche.com).
With these purchases, the Strategic National Stockpile will have a total of 26 million treatment courses of antiviral drugs for distribution. "Our ultimate goal is to stockpile sufficient quantities of antiviral drugs to treat 25% of the US population," said HHS Secretary Michael Leavitt, in a prepared statement. “We also hope these purchases will stimulate development of expanded domestic production capacity in order to accommodate subsequent needs through normal commercial transactions."
The US government has outlined a strategy for pandemic flu that includes establishing the new International Partnership on Avian and Pandemic Influenza, stockpiling antiviral medications, enhancing domestic capacity to develop and manufacture influenza vaccines and dose-sparing technology, expanding early-warning systems domestically and abroad, and providing new funding and initiatives for local and state level preparedness.
Separately, GSK submitted a biologics license application for the “FluLaval” influenza virus vaccine to the US Food and Drug Administration. GSK added FluLaval with its acquisition of the Canadian vaccine manufacturer ID Biomedical Corporation in December 2005. The acquisition added to GSK’s influenza product portfolio, which also includes the “Fluarix” influenza virus vaccine, which was approved by FDA on August 2005. If granted US marketing approval for FluLaval, GSK expects to provide up to 30 million doses of seasonal influenza vaccine (FluLaval and Fluarix) to the US market for the 2006–2007 flu season.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.